生物标志物的随访能更好地预测COVID-19患者的不良预后。
The Follow-Up of Biomarkers Better Predicts the Poor Outcome in COVID-19 Patients.
作者信息
Basoglu Ozen K, Ozhan Mustafa Hikmet, Ekren Pervin Korkmaz, Ak Gunes, Tasbakan Mehmet Sezai, Sayiner Abdullah
机构信息
Department of Chest Diseases, Ege University Faculty of Medicine
Department of Chest Diseases, Ege University Faculty of Medicine.
出版信息
Ann Clin Lab Sci. 2020 Nov;50(6):848-851.
OBJECTIVE
To investigate the course of biomarkers on admission and follow-up in order to identify early predictors for poor outcome in COVID-19 patients.
METHODS
In this study, 132 COVID-19 patients were classified as good outcome (n=62) and poor outcome (n=70) groups. Laboratory parameters were evaluated on admission and within 5-7 days after hospitalization.
RESULTS
Baseline levels of neutrophil-lymphocyte ratio, CRP, procalcitonin, ferritin, D-dimer and LDH were higher (<0.01); lymphocyte count was lower in the poor outcome patients. During follow-up there was a larger decrease in lymphocyte count and more prominent increases in other biomarkers (<0.001). In ROC analysis, the AUCs strongly indicated the poor outcome on days 5-7 of the hospitalization.
CONCLUSIONS
This study suggests that the follow-up measurements of the biomarkers better predict the poor outcome in COVID-19 pneumonia.
目的
研究入院时及随访期间生物标志物的变化过程，以确定新冠病毒疾病（COVID-19）患者不良预后的早期预测指标。
方法
在本研究中，132例COVID-19患者被分为预后良好组（n = 62）和预后不良组（n = 70）。在入院时及住院后5 - 7天评估实验室参数。
结果
预后不良患者的中性粒细胞与淋巴细胞比值、CRP、降钙素原、铁蛋白、D - 二聚体和乳酸脱氢酶的基线水平较高（<0.01）；淋巴细胞计数较低。在随访期间，淋巴细胞计数下降幅度更大，其他生物标志物升高更显著（<0.001）。在ROC分析中，曲线下面积（AUC）强烈表明在住院第5 - 7天时预后不良。
结论
本研究表明，对生物标志物进行随访测量能更好地预测COVID-19肺炎的不良预后。
Zotero 插件